黑色素瘤中肿瘤汇效应对黑色素配体[131I]ICF01012的影响及其对靶向放射性核素治疗的启示
本研究探讨肿瘤汇效应是否影响黑色素靶向放射药物[131I]ICF01012在转移性黑色素瘤中的生物分布。采用同系小鼠黑色素瘤模型进行离体生物分布研究,发现肿瘤摄取与眼部摄取呈负相关(r=-0.7485,p<0.0001),大肿瘤负荷小鼠眼部摄取显著降低(24小时-41.8%,72小时-47.4%,p=0.022)。结果提示肿瘤负荷影响该药物在非靶器官的分布,可能对剂量学和毒性缓解有临床意义。
要点
- 在同系小鼠黑色素瘤模型中,[131I]ICF01012注射后24小时肿瘤摄取为18.8±4.5 IA%/g。
- 肿瘤摄取与眼部摄取呈负相关(r=-0.7485,p<0.0001)。
- 大肿瘤负荷小鼠眼部摄取在24小时降低41.8%、72小时降低47.4%(p=0.022)。
核心结论
- 这些发现提示肿瘤负荷影响[131I]ICF01012在非靶器官中的分布,对转移性黑色素瘤放射性药物治疗的剂量学和毒性缓解具有潜在临床意义。
- 需要进一步研究以完善剂量学模型并评估该效应在人体中的转化相关性。
研究设计与样本
- 采用同系小鼠黑色素瘤模型(B16-F10、B16-OVA、B16BL6)进行离体生物分布研究,将肿瘤体积与放射性药物摄取进行相关性分析。
主要发现
- 在模型中,γ计数显示注射[131I]ICF01012后24小时肿瘤摄取显著,为18.8±4.5 IA%/g。
- 肿瘤摄取与眼部摄取呈负相关(r=-0.7485,p<0.0001)。
- 在大肿瘤负荷小鼠中观察到眼部摄取显著降低,24小时降低41.8%、72小时降低47.4%(p=0.022)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以完善剂量学模型并评估该效应在人体中的转化相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The tumor sink effect refers to the sequestration of a radiopharmaceutical compound by tumors, leading to a reduced bioavailability in non-target organs and potential alterations in radiopharmaceuticals distribution. This phenomenon has been widely studied in neuroendocrine, thyroid, and prostate cancers but remains unexplored for melanin-targeting radiopharmaceuticals in metastatic melanoma. [131I]ICF01012, an arylcarboxamide-derived radiopharmaceutical developed by our team, binds specifically to intra- and extracellular melanin. Given its high ocular uptake, we investigated whether tumor burden influences its biodistribution, particularly in organs at risk such as eyes. RESULTS: We conducted an ex vivo biodistribution study using syngeneic murine melanoma models (B16-F10, B16-OVA, B16BL6) and correlated tumor volume with radiopharmaceutical uptake. In models, γ-counting revealed significant tumor uptake (18.8 ± 4.5 IA%/g at 24 h after injection of [131I]ICF01012), which was inversely correlated with ocular uptake (r = -0.7485, p < 0.0001). A significant reduction in ocular uptake was observed in mice with large tumor burdens (-41.8% at 24 h, -47.4% at 72 h, p = 0.022). CONCLUSION: These findings suggest that tumor burden impacts [131I]ICF01012 distribution in non-target organs, with potential clinical implications for dosimetry and toxicity mitigation in radiopharmaceutical therapy for metastatic melanoma. Further studies are needed to refine dosimetric models and assess the translational relevance of this effect in human subjects.
引用
- Jouberton E, Besse S, Billoux T, et al. Tumor sink effect on melanin-ligand [131I]ICF01012 in melanoma and its implications for targeted radionuclide therapy. EJNMMI Res. 2025. PMID: 41003926. doi:10.1186/s13550-025-01319-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。